Neratinib as extended adjuvant therapy in patients with HER2-positive/HR-positive early breast cancer: German HTA-driven analyses from the ExteNET study

Saved in:
Bibliographic Details
Published inBreast (Edinburgh) Vol. 56; p. S17
Main Authors Lüftner, D., Tesch, H., Schmidt, M., Hartkopf, A., Streicher, S., Resch, A., Genovese, L., Rosé, C., Valenti, R., Harbeck, N.
Format Journal Article
LanguageEnglish
Published Elsevier 01.04.2021
Online AccessGet full text

Cover

More Information
ISSN:0960-9776
1532-3080
DOI:10.1016/S0960-9776(21)00089-8